Imricor Medical Systems, Inc.
Imricor Medical Systems, Inc. (IMR.AX) Stock Competitors & Peer Comparison
See (IMR.AX) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| IMR.AX | A$1.94 | +1.04% | 474.1M | -15.83 | -A$0.12 | N/A |
| COH.AX | A$175.04 | +4.86% | 11.1B | 32.09 | A$5.27 | +2.54% |
| 4DX.AX | A$5.95 | +5.50% | 3.2B | -13.90 | -A$0.40 | N/A |
| PNV.AX | A$1.00 | +12.36% | 645.9M | 93.50 | A$0.01 | N/A |
| AVR.AX | A$7.88 | +2.34% | 268.6M | -1.97 | -A$3.71 | N/A |
| EBR.AX | A$0.58 | -9.38% | 261.2M | -3.41 | -A$0.17 | N/A |
| ARX.AX | A$0.59 | -1.67% | 205.6M | -59.50 | -A$0.01 | N/A |
| EMV.AX | A$1.57 | +1.95% | 146.8M | -13.17 | -A$0.12 | N/A |
| SOM.AX | A$0.62 | -3.88% | 142.4M | -65.00 | -A$0.01 | N/A |
| AVH.AX | A$1.10 | +1.38% | 133.5M | -2.11 | -A$0.51 | N/A |
Stock Comparison
IMR.AX vs COH.AX Comparison April 2026
IMR.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMR.AX stands at 474.1M. In comparison, COH.AX has a market cap of 11.1B. Regarding current trading prices, IMR.AX is priced at A$1.94, while COH.AX trades at A$175.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMR.AX currently has a P/E ratio of -15.83, whereas COH.AX's P/E ratio is 32.09. In terms of profitability, IMR.AX's ROE is -1.10%, compared to COH.AX's ROE of +0.18%. Regarding short-term risk, IMR.AX is more volatile compared to COH.AX. This indicates potentially higher risk in terms of short-term price fluctuations for IMR.AX.Check COH.AX's competition here
IMR.AX vs 4DX.AX Comparison April 2026
IMR.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMR.AX stands at 474.1M. In comparison, 4DX.AX has a market cap of 3.2B. Regarding current trading prices, IMR.AX is priced at A$1.94, while 4DX.AX trades at A$5.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMR.AX currently has a P/E ratio of -15.83, whereas 4DX.AX's P/E ratio is -13.90. In terms of profitability, IMR.AX's ROE is -1.10%, compared to 4DX.AX's ROE of -8.91%. Regarding short-term risk, IMR.AX is less volatile compared to 4DX.AX. This indicates potentially lower risk in terms of short-term price fluctuations for IMR.AX.Check 4DX.AX's competition here
IMR.AX vs PNV.AX Comparison April 2026
IMR.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMR.AX stands at 474.1M. In comparison, PNV.AX has a market cap of 645.9M. Regarding current trading prices, IMR.AX is priced at A$1.94, while PNV.AX trades at A$1.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMR.AX currently has a P/E ratio of -15.83, whereas PNV.AX's P/E ratio is 93.50. In terms of profitability, IMR.AX's ROE is -1.10%, compared to PNV.AX's ROE of +0.12%. Regarding short-term risk, IMR.AX is less volatile compared to PNV.AX. This indicates potentially lower risk in terms of short-term price fluctuations for IMR.AX.Check PNV.AX's competition here
IMR.AX vs AVR.AX Comparison April 2026
IMR.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMR.AX stands at 474.1M. In comparison, AVR.AX has a market cap of 268.6M. Regarding current trading prices, IMR.AX is priced at A$1.94, while AVR.AX trades at A$7.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMR.AX currently has a P/E ratio of -15.83, whereas AVR.AX's P/E ratio is -1.97. In terms of profitability, IMR.AX's ROE is -1.10%, compared to AVR.AX's ROE of -7.74%. Regarding short-term risk, IMR.AX is less volatile compared to AVR.AX. This indicates potentially lower risk in terms of short-term price fluctuations for IMR.AX.Check AVR.AX's competition here
IMR.AX vs EBR.AX Comparison April 2026
IMR.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMR.AX stands at 474.1M. In comparison, EBR.AX has a market cap of 261.2M. Regarding current trading prices, IMR.AX is priced at A$1.94, while EBR.AX trades at A$0.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMR.AX currently has a P/E ratio of -15.83, whereas EBR.AX's P/E ratio is -3.41. In terms of profitability, IMR.AX's ROE is -1.10%, compared to EBR.AX's ROE of -1.52%. Regarding short-term risk, IMR.AX is less volatile compared to EBR.AX. This indicates potentially lower risk in terms of short-term price fluctuations for IMR.AX.Check EBR.AX's competition here
IMR.AX vs ARX.AX Comparison April 2026
IMR.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMR.AX stands at 474.1M. In comparison, ARX.AX has a market cap of 205.6M. Regarding current trading prices, IMR.AX is priced at A$1.94, while ARX.AX trades at A$0.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMR.AX currently has a P/E ratio of -15.83, whereas ARX.AX's P/E ratio is -59.50. In terms of profitability, IMR.AX's ROE is -1.10%, compared to ARX.AX's ROE of -0.04%. Regarding short-term risk, IMR.AX is more volatile compared to ARX.AX. This indicates potentially higher risk in terms of short-term price fluctuations for IMR.AX.Check ARX.AX's competition here
IMR.AX vs EMV.AX Comparison April 2026
IMR.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMR.AX stands at 474.1M. In comparison, EMV.AX has a market cap of 146.8M. Regarding current trading prices, IMR.AX is priced at A$1.94, while EMV.AX trades at A$1.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMR.AX currently has a P/E ratio of -15.83, whereas EMV.AX's P/E ratio is -13.17. In terms of profitability, IMR.AX's ROE is -1.10%, compared to EMV.AX's ROE of -0.70%. Regarding short-term risk, IMR.AX is more volatile compared to EMV.AX. This indicates potentially higher risk in terms of short-term price fluctuations for IMR.AX.Check EMV.AX's competition here
IMR.AX vs SOM.AX Comparison April 2026
IMR.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMR.AX stands at 474.1M. In comparison, SOM.AX has a market cap of 142.4M. Regarding current trading prices, IMR.AX is priced at A$1.94, while SOM.AX trades at A$0.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMR.AX currently has a P/E ratio of -15.83, whereas SOM.AX's P/E ratio is -65.00. In terms of profitability, IMR.AX's ROE is -1.10%, compared to SOM.AX's ROE of -0.05%. Regarding short-term risk, IMR.AX is less volatile compared to SOM.AX. This indicates potentially lower risk in terms of short-term price fluctuations for IMR.AX.Check SOM.AX's competition here
IMR.AX vs AVH.AX Comparison April 2026
IMR.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMR.AX stands at 474.1M. In comparison, AVH.AX has a market cap of 133.5M. Regarding current trading prices, IMR.AX is priced at A$1.94, while AVH.AX trades at A$1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMR.AX currently has a P/E ratio of -15.83, whereas AVH.AX's P/E ratio is -2.11. In terms of profitability, IMR.AX's ROE is -1.10%, compared to AVH.AX's ROE of +4.78%. Regarding short-term risk, IMR.AX is more volatile compared to AVH.AX. This indicates potentially higher risk in terms of short-term price fluctuations for IMR.AX.Check AVH.AX's competition here
IMR.AX vs CYC.AX Comparison April 2026
IMR.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMR.AX stands at 474.1M. In comparison, CYC.AX has a market cap of 102.7M. Regarding current trading prices, IMR.AX is priced at A$1.94, while CYC.AX trades at A$0.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMR.AX currently has a P/E ratio of -15.83, whereas CYC.AX's P/E ratio is -5.31. In terms of profitability, IMR.AX's ROE is -1.10%, compared to CYC.AX's ROE of -0.54%. Regarding short-term risk, IMR.AX is less volatile compared to CYC.AX. This indicates potentially lower risk in terms of short-term price fluctuations for IMR.AX.Check CYC.AX's competition here
IMR.AX vs CMP.AX Comparison April 2026
IMR.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMR.AX stands at 474.1M. In comparison, CMP.AX has a market cap of 55.9M. Regarding current trading prices, IMR.AX is priced at A$1.94, while CMP.AX trades at A$0.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMR.AX currently has a P/E ratio of -15.83, whereas CMP.AX's P/E ratio is -28.00. In terms of profitability, IMR.AX's ROE is -1.10%, compared to CMP.AX's ROE of +0.00%. Regarding short-term risk, IMR.AX is more volatile compared to CMP.AX. This indicates potentially higher risk in terms of short-term price fluctuations for IMR.AX.Check CMP.AX's competition here
IMR.AX vs RSH.AX Comparison April 2026
IMR.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMR.AX stands at 474.1M. In comparison, RSH.AX has a market cap of 52M. Regarding current trading prices, IMR.AX is priced at A$1.94, while RSH.AX trades at A$0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMR.AX currently has a P/E ratio of -15.83, whereas RSH.AX's P/E ratio is -3.30. In terms of profitability, IMR.AX's ROE is -1.10%, compared to RSH.AX's ROE of -4.12%. Regarding short-term risk, IMR.AX is less volatile compared to RSH.AX. This indicates potentially lower risk in terms of short-term price fluctuations for IMR.AX.Check RSH.AX's competition here
IMR.AX vs MX1.AX Comparison April 2026
IMR.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMR.AX stands at 474.1M. In comparison, MX1.AX has a market cap of 39.9M. Regarding current trading prices, IMR.AX is priced at A$1.94, while MX1.AX trades at A$0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMR.AX currently has a P/E ratio of -15.83, whereas MX1.AX's P/E ratio is -2.75. In terms of profitability, IMR.AX's ROE is -1.10%, compared to MX1.AX's ROE of -1.80%. Regarding short-term risk, IMR.AX is less volatile compared to MX1.AX. This indicates potentially lower risk in terms of short-term price fluctuations for IMR.AX.Check MX1.AX's competition here
IMR.AX vs HMD.AX Comparison April 2026
IMR.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMR.AX stands at 474.1M. In comparison, HMD.AX has a market cap of 39.6M. Regarding current trading prices, IMR.AX is priced at A$1.94, while HMD.AX trades at A$0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMR.AX currently has a P/E ratio of -15.83, whereas HMD.AX's P/E ratio is -5.00. In terms of profitability, IMR.AX's ROE is -1.10%, compared to HMD.AX's ROE of -4.18%. Regarding short-term risk, IMR.AX is more volatile compared to HMD.AX. This indicates potentially higher risk in terms of short-term price fluctuations for IMR.AX.Check HMD.AX's competition here
IMR.AX vs CSX.AX Comparison April 2026
IMR.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMR.AX stands at 474.1M. In comparison, CSX.AX has a market cap of 37.8M. Regarding current trading prices, IMR.AX is priced at A$1.94, while CSX.AX trades at A$0.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMR.AX currently has a P/E ratio of -15.83, whereas CSX.AX's P/E ratio is 23.00. In terms of profitability, IMR.AX's ROE is -1.10%, compared to CSX.AX's ROE of +0.09%. Regarding short-term risk, IMR.AX is more volatile compared to CSX.AX. This indicates potentially higher risk in terms of short-term price fluctuations for IMR.AX.Check CSX.AX's competition here
IMR.AX vs EYE.AX Comparison April 2026
IMR.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMR.AX stands at 474.1M. In comparison, EYE.AX has a market cap of 34.2M. Regarding current trading prices, IMR.AX is priced at A$1.94, while EYE.AX trades at A$0.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMR.AX currently has a P/E ratio of -15.83, whereas EYE.AX's P/E ratio is -6.00. In terms of profitability, IMR.AX's ROE is -1.10%, compared to EYE.AX's ROE of -0.40%. Regarding short-term risk, IMR.AX is less volatile compared to EYE.AX. This indicates potentially lower risk in terms of short-term price fluctuations for IMR.AX.Check EYE.AX's competition here
IMR.AX vs IPD.AX Comparison April 2026
IMR.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMR.AX stands at 474.1M. In comparison, IPD.AX has a market cap of 30.6M. Regarding current trading prices, IMR.AX is priced at A$1.94, while IPD.AX trades at A$0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMR.AX currently has a P/E ratio of -15.83, whereas IPD.AX's P/E ratio is -1.50. In terms of profitability, IMR.AX's ROE is -1.10%, compared to IPD.AX's ROE of -1.65%. Regarding short-term risk, IMR.AX is less volatile compared to IPD.AX. This indicates potentially lower risk in terms of short-term price fluctuations for IMR.AX.Check IPD.AX's competition here
IMR.AX vs LBT.AX Comparison April 2026
IMR.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMR.AX stands at 474.1M. In comparison, LBT.AX has a market cap of 29.9M. Regarding current trading prices, IMR.AX is priced at A$1.94, while LBT.AX trades at A$0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMR.AX currently has a P/E ratio of -15.83, whereas LBT.AX's P/E ratio is -0.42. In terms of profitability, IMR.AX's ROE is -1.10%, compared to LBT.AX's ROE of -3.23%. Regarding short-term risk, IMR.AX is more volatile compared to LBT.AX. This indicates potentially higher risk in terms of short-term price fluctuations for IMR.AX.Check LBT.AX's competition here
IMR.AX vs AT1.AX Comparison April 2026
IMR.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMR.AX stands at 474.1M. In comparison, AT1.AX has a market cap of 27.5M. Regarding current trading prices, IMR.AX is priced at A$1.94, while AT1.AX trades at A$0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMR.AX currently has a P/E ratio of -15.83, whereas AT1.AX's P/E ratio is -3.40. In terms of profitability, IMR.AX's ROE is -1.10%, compared to AT1.AX's ROE of -0.58%. Regarding short-term risk, IMR.AX is less volatile compared to AT1.AX. This indicates potentially lower risk in terms of short-term price fluctuations for IMR.AX.Check AT1.AX's competition here
IMR.AX vs CDX.AX Comparison April 2026
IMR.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMR.AX stands at 474.1M. In comparison, CDX.AX has a market cap of 19.8M. Regarding current trading prices, IMR.AX is priced at A$1.94, while CDX.AX trades at A$0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMR.AX currently has a P/E ratio of -15.83, whereas CDX.AX's P/E ratio is -0.90. In terms of profitability, IMR.AX's ROE is -1.10%, compared to CDX.AX's ROE of -2.17%. Regarding short-term risk, IMR.AX is less volatile compared to CDX.AX. This indicates potentially lower risk in terms of short-term price fluctuations for IMR.AX.Check CDX.AX's competition here
IMR.AX vs CBL.AX Comparison April 2026
IMR.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMR.AX stands at 474.1M. In comparison, CBL.AX has a market cap of 17.6M. Regarding current trading prices, IMR.AX is priced at A$1.94, while CBL.AX trades at A$0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMR.AX currently has a P/E ratio of -15.83, whereas CBL.AX's P/E ratio is -2.75. In terms of profitability, IMR.AX's ROE is -1.10%, compared to CBL.AX's ROE of -0.98%. Regarding short-term risk, IMR.AX is more volatile compared to CBL.AX. This indicates potentially higher risk in terms of short-term price fluctuations for IMR.AX.Check CBL.AX's competition here
IMR.AX vs NTI.AX Comparison April 2026
IMR.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMR.AX stands at 474.1M. In comparison, NTI.AX has a market cap of 13.1M. Regarding current trading prices, IMR.AX is priced at A$1.94, while NTI.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMR.AX currently has a P/E ratio of -15.83, whereas NTI.AX's P/E ratio is -1.30. In terms of profitability, IMR.AX's ROE is -1.10%, compared to NTI.AX's ROE of -0.87%. Regarding short-term risk, IMR.AX is less volatile compared to NTI.AX. This indicates potentially lower risk in terms of short-term price fluctuations for IMR.AX.Check NTI.AX's competition here
IMR.AX vs RNO.AX Comparison April 2026
IMR.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMR.AX stands at 474.1M. In comparison, RNO.AX has a market cap of 11.5M. Regarding current trading prices, IMR.AX is priced at A$1.94, while RNO.AX trades at A$0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMR.AX currently has a P/E ratio of -15.83, whereas RNO.AX's P/E ratio is -1.00. In terms of profitability, IMR.AX's ROE is -1.10%, compared to RNO.AX's ROE of +15.91%. Regarding short-term risk, IMR.AX is more volatile compared to RNO.AX. This indicates potentially higher risk in terms of short-term price fluctuations for IMR.AX.Check RNO.AX's competition here
IMR.AX vs TRU.AX Comparison April 2026
IMR.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMR.AX stands at 474.1M. In comparison, TRU.AX has a market cap of 10.1M. Regarding current trading prices, IMR.AX is priced at A$1.94, while TRU.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMR.AX currently has a P/E ratio of -15.83, whereas TRU.AX's P/E ratio is -1.35. In terms of profitability, IMR.AX's ROE is -1.10%, compared to TRU.AX's ROE of -1.13%. Regarding short-term risk, IMR.AX is more volatile compared to TRU.AX. This indicates potentially higher risk in terms of short-term price fluctuations for IMR.AX.Check TRU.AX's competition here
IMR.AX vs OSL.AX Comparison April 2026
IMR.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMR.AX stands at 474.1M. In comparison, OSL.AX has a market cap of 9.4M. Regarding current trading prices, IMR.AX is priced at A$1.94, while OSL.AX trades at A$0.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMR.AX currently has a P/E ratio of -15.83, whereas OSL.AX's P/E ratio is -0.53. In terms of profitability, IMR.AX's ROE is -1.10%, compared to OSL.AX's ROE of -3.72%. Regarding short-term risk, IMR.AX is more volatile compared to OSL.AX. This indicates potentially higher risk in terms of short-term price fluctuations for IMR.AX.Check OSL.AX's competition here
IMR.AX vs IRX.AX Comparison April 2026
IMR.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMR.AX stands at 474.1M. In comparison, IRX.AX has a market cap of 6.9M. Regarding current trading prices, IMR.AX is priced at A$1.94, while IRX.AX trades at A$0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMR.AX currently has a P/E ratio of -15.83, whereas IRX.AX's P/E ratio is -2.80. In terms of profitability, IMR.AX's ROE is -1.10%, compared to IRX.AX's ROE of +2.96%. Regarding short-term risk, IMR.AX is less volatile compared to IRX.AX. This indicates potentially lower risk in terms of short-term price fluctuations for IMR.AX.Check IRX.AX's competition here
IMR.AX vs OVN.AX Comparison April 2026
IMR.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMR.AX stands at 474.1M. In comparison, OVN.AX has a market cap of 4.8M. Regarding current trading prices, IMR.AX is priced at A$1.94, while OVN.AX trades at A$0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMR.AX currently has a P/E ratio of -15.83, whereas OVN.AX's P/E ratio is -0.40. In terms of profitability, IMR.AX's ROE is -1.10%, compared to OVN.AX's ROE of -0.80%. Regarding short-term risk, IMR.AX is less volatile compared to OVN.AX. This indicates potentially lower risk in terms of short-term price fluctuations for IMR.AX.Check OVN.AX's competition here
IMR.AX vs ALT.AX Comparison April 2026
IMR.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMR.AX stands at 474.1M. In comparison, ALT.AX has a market cap of 4.6M. Regarding current trading prices, IMR.AX is priced at A$1.94, while ALT.AX trades at A$0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMR.AX currently has a P/E ratio of -15.83, whereas ALT.AX's P/E ratio is N/A. In terms of profitability, IMR.AX's ROE is -1.10%, compared to ALT.AX's ROE of -2.31%. Regarding short-term risk, IMR.AX is more volatile compared to ALT.AX. This indicates potentially higher risk in terms of short-term price fluctuations for IMR.AX.Check ALT.AX's competition here
IMR.AX vs UBI.AX Comparison April 2026
IMR.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMR.AX stands at 474.1M. In comparison, UBI.AX has a market cap of 4.2M. Regarding current trading prices, IMR.AX is priced at A$1.94, while UBI.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMR.AX currently has a P/E ratio of -15.83, whereas UBI.AX's P/E ratio is -0.23. In terms of profitability, IMR.AX's ROE is -1.10%, compared to UBI.AX's ROE of -1.19%. Regarding short-term risk, IMR.AX is less volatile compared to UBI.AX. This indicates potentially lower risk in terms of short-term price fluctuations for IMR.AX.Check UBI.AX's competition here
IMR.AX vs ADR.AX Comparison April 2026
IMR.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMR.AX stands at 474.1M. In comparison, ADR.AX has a market cap of 3.9M. Regarding current trading prices, IMR.AX is priced at A$1.94, while ADR.AX trades at A$0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMR.AX currently has a P/E ratio of -15.83, whereas ADR.AX's P/E ratio is -0.20. In terms of profitability, IMR.AX's ROE is -1.10%, compared to ADR.AX's ROE of +4.60%. Regarding short-term risk, IMR.AX is less volatile compared to ADR.AX. This indicates potentially lower risk in terms of short-term price fluctuations for IMR.AX.Check ADR.AX's competition here
IMR.AX vs VTI.AX Comparison April 2026
IMR.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMR.AX stands at 474.1M. In comparison, VTI.AX has a market cap of 3.7M. Regarding current trading prices, IMR.AX is priced at A$1.94, while VTI.AX trades at A$0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMR.AX currently has a P/E ratio of -15.83, whereas VTI.AX's P/E ratio is -0.55. In terms of profitability, IMR.AX's ROE is -1.10%, compared to VTI.AX's ROE of -0.57%. Regarding short-term risk, IMR.AX is more volatile compared to VTI.AX. This indicates potentially higher risk in terms of short-term price fluctuations for IMR.AX.Check VTI.AX's competition here
IMR.AX vs AMT.AX Comparison April 2026
IMR.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMR.AX stands at 474.1M. In comparison, AMT.AX has a market cap of 3.5M. Regarding current trading prices, IMR.AX is priced at A$1.94, while AMT.AX trades at A$0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMR.AX currently has a P/E ratio of -15.83, whereas AMT.AX's P/E ratio is -1.45. In terms of profitability, IMR.AX's ROE is -1.10%, compared to AMT.AX's ROE of -11.52%. Regarding short-term risk, IMR.AX is less volatile compared to AMT.AX. This indicates potentially lower risk in terms of short-term price fluctuations for IMR.AX.Check AMT.AX's competition here
IMR.AX vs UCM.AX Comparison April 2026
IMR.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMR.AX stands at 474.1M. In comparison, UCM.AX has a market cap of 3.1M. Regarding current trading prices, IMR.AX is priced at A$1.94, while UCM.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMR.AX currently has a P/E ratio of -15.83, whereas UCM.AX's P/E ratio is -0.60. In terms of profitability, IMR.AX's ROE is -1.10%, compared to UCM.AX's ROE of -3.58%. Regarding short-term risk, IMR.AX is more volatile compared to UCM.AX. This indicates potentially higher risk in terms of short-term price fluctuations for IMR.AX.Check UCM.AX's competition here